Press release
May 7, 2026
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Neumora Therapeutics, Inc. (NMRA)
KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation and NMRA-898 in schizophrenia with clinical data expected for each program in the second half of 2026